199 related articles for article (PubMed ID: 29644769)
1. Reactive Chemical Probes: Beyond the Kinase Cysteinome.
Jones LH
Angew Chem Int Ed Engl; 2018 Jul; 57(30):9220-9223. PubMed ID: 29644769
[TBL] [Abstract][Full Text] [Related]
2. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
3. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
4. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
5. Lysine-Targeted Inhibitors and Chemoproteomic Probes.
Cuesta A; Taunton J
Annu Rev Biochem; 2019 Jun; 88():365-381. PubMed ID: 30633551
[TBL] [Abstract][Full Text] [Related]
6. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM; Taunton J
Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
[TBL] [Abstract][Full Text] [Related]
7. Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q; Sabnis Y; Zhao Z; Zhang T; Buhrlage SJ; Jones LH; Gray NS
Chem Biol; 2013 Feb; 20(2):146-59. PubMed ID: 23438744
[TBL] [Abstract][Full Text] [Related]
8. Reversible lysine-targeted probes reveal residence time-based kinase selectivity.
Yang T; Cuesta A; Wan X; Craven GB; Hirakawa B; Khamphavong P; May JR; Kath JC; Lapek JD; Niessen S; Burlingame AL; Carelli JD; Taunton J
Nat Chem Biol; 2022 Sep; 18(9):934-941. PubMed ID: 35590003
[TBL] [Abstract][Full Text] [Related]
9. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
10. Chemical Probes for Understudied Kinases: Challenges and Opportunities.
Serafim RAM; Elkins JM; Zuercher WJ; Laufer SA; Gehringer M
J Med Chem; 2022 Jan; 65(2):1132-1170. PubMed ID: 34477374
[TBL] [Abstract][Full Text] [Related]
11. Cysteinome: The first comprehensive database for proteins with targetable cysteine and their covalent inhibitors.
Wu S; Luo Howard H; Wang H; Zhao W; Hu Q; Yang Y
Biochem Biophys Res Commun; 2016 Sep; 478(3):1268-73. PubMed ID: 27553277
[TBL] [Abstract][Full Text] [Related]
12. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.
Zhao Z; Liu Q; Bliven S; Xie L; Bourne PE
J Med Chem; 2017 Apr; 60(7):2879-2889. PubMed ID: 28326775
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomics of kinase inhibitor targets and mechanisms.
Daub H
ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
[TBL] [Abstract][Full Text] [Related]
14. Optimized chemical proteomics assay for kinase inhibitor profiling.
Médard G; Pachl F; Ruprecht B; Klaeger S; Heinzlmeir S; Helm D; Qiao H; Ku X; Wilhelm M; Kuehne T; Wu Z; Dittmann A; Hopf C; Kramer K; Kuster B
J Proteome Res; 2015 Mar; 14(3):1574-86. PubMed ID: 25660469
[TBL] [Abstract][Full Text] [Related]
15. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.
Peters EC; Gray NS
ACS Chem Biol; 2007 Oct; 2(10):661-4. PubMed ID: 18041816
[TBL] [Abstract][Full Text] [Related]
16. Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions.
Hu C; Dong X
Curr Med Chem; 2019; 26(31):5811-5824. PubMed ID: 30009703
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
Forster M; Gehringer M; Laufer SA
Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
[TBL] [Abstract][Full Text] [Related]
18. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
[TBL] [Abstract][Full Text] [Related]
19. Pseudokinases: update on their functions and evaluation as new drug targets.
Byrne DP; Foulkes DM; Eyers PA
Future Med Chem; 2017 Jan; 9(2):245-265. PubMed ID: 28097887
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M
Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]